UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other juri ...

Core Insights - Bausch + Lomb reported $1.28 billion in revenue for Q2 2025, a 5.1% year-over-year increase, with an EPS of $0.07 compared to $0.13 a year ago, indicating a decline in earnings per share [1] - The revenue exceeded the Zacks Consensus Estimate of $1.25 billion by 2.37%, while the EPS surpassed the consensus estimate of $0.06 by 16.67% [1] Revenue Breakdown - Vision Care revenues reached $753 million, exceeding the average estimate of $742.89 million, reflecting an 8% year-over-year increase [4] - Surgical revenues were reported at $216 million, surpassing the average estimate of $180.14 million, with a year-over-year change of 3.4% [4] - Pharmaceutical revenues totaled $309 million, slightly below the estimated $329.52 million, showing a minor decline of 0.3% year-over-year [4] - Total product sales amounted to $1.27 billion, exceeding the average estimate of $1.25 billion, representing a 4.9% year-over-year increase [4] - Other revenues were reported at $6 million, above the estimated $4 million, marking a significant 100% year-over-year increase [4] Stock Performance - Bausch + Lomb shares have returned +8.9% over the past month, outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Bausch + Lomb (BLCO) Q2 2025 Earnings Call July 30, 2025 08:00 AM ET Company ParticipantsGeorge Gadkowski - VP & Head of IR & Business InsightsBrent Saunders - CEO & ChairmanSam Eldessouky - EVP & CFOYoung Li - Senior VP - Equity ResearchYehia Hashad - EVP - Research and Development & CMOJoanne Wuensch. - Managing DirectorConference Call ParticipantsMatt Miksic - Equity Research AnalystNone - AnalystDouglas Miehm - AnalystGary Nachman - MD - BioPharma/Biotech Equity Research AnalystOperatorGood morning, and ...

Financial Data and Key Metrics Changes - Total company revenue for Q2 2025 was $1,278 million, reflecting a year-over-year growth of 3% [13] - Excluding the impact of the Envista recall, total company revenue grew by 6% in the quarter [14] - Adjusted gross margin for Q2 was 60.6%, representing a 130 basis points decrease year-over-year [24] - Adjusted EBITDA for Q2, excluding acquired IPR&D, was $192 million, absorbing a one-time impact of $19 million from the investor recall [25] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q2 was $753 million, increasing by 6%, driven by growth in both consumer and contact lenses [15] - The dry eye portfolio generated $115 million in revenue in Q2, representing 19% growth [16] - Surgical segment revenue was $216 million, an increase of 1%, but would have been 15% growth excluding the recall [19] - Pharma segment revenue was $309 million in Q2, representing a decline of 1% [21] Market Data and Key Metrics Changes - U.S. contact lens revenue grew by 11%, EMEA by 11%, LATAM by 25%, Japan by 3%, and China by 7% [19] - The Daily SiHy contact lens franchise grew by 36% in Q2, continuing to be the fastest-growing brand [18] - The U.S. branded Rx business in Pharma was up 8% in Q2, driven by growth in MyBu and Xiidra [21] Company Strategy and Development Direction - The company is focused on innovation and has a robust pipeline that represents its future [7] - The strategic roadmap aims to accelerate growth and improve operational excellence [5] - The company plans to showcase potential game changers at the upcoming Investor Day [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the team's ability to overcome challenges and transform the company [42] - The company anticipates steady improvement in the U.S. Generics business in the second half of the year [24] - Management remains optimistic about the contact lens market and expects it to remain healthy [75] Other Important Information - The company raised its full-year revenue guidance to a range of $5,050 million to $5,150 million, reflecting constant currency growth of approximately 5% to 7% [26] - Adjusted EBITDA guidance was raised to a range of $860 million to $910 million [27] - The company successfully executed a refinancing of $3,100 million of its debt, extending maturities to 2031 [26] Q&A Session Summary Question: Highlights informing the decision to recommit to the company - Management expressed deep confidence in the team, products, and R&D pipeline, emphasizing the opportunity to transform the company [41] Question: Quantifying the tariff impact and strategy in Pharma - Management noted that the tariff impact is now estimated at 40 basis points for 2025, which is absorbed in the guidance [56] Question: Update on the product pipeline and future expectations - Management indicated that the contact lens R&D projects are at their best in the company's history, with significant advancements expected [98]

2Q25 Financial Results Forward-Looking Statements; Non-GAAP Information This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2025 full-year guidance), our roadmap to accelerate growth and the steps thereof ...

Exhibit 99.1 Bausch + Lomb Announces Second-Quarter 2025 Results VAUGHAN, Ontario, July 30, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world," said Brent Saunders, chairman and CEO, Bausch + ...

Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a product recall and subsequent stock price drop [1][2]. Group 1: Product Recall and Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses from its enVista platform due to reports of toxic anterior segment syndrome (TASS), which is a complication associated with cataract surgery [2]. - The recall has raised short-term concerns regarding product safety and may lead to increased regulatory scrutiny [2]. - Following the recall announcement, Bausch + Lomb's stock price fell by $1.50 per share, representing a 10.6% decrease, closing at $15.00 on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Bausch + Lomb on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information related to the claims [3].

Core Viewpoint - The Schall Law Firm is investigating Bausch + Lomb Corporation for potential violations of securities laws, focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline compared to a net income of $24 million in the same period of the previous year [2]. - The company has lowered its full-year growth outlook, attributing part of this change to the recall of its enVista product [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bausch + Lomb Corporation and its executives [1] Group 1: Product Recall and Stock Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses due to reports of toxic anterior segment syndrome, leading to a stock price drop of $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [3] - Following the recall, on April 30, 2025, Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline from an adjusted net income of $24 million in Q1 2024 [4] - The company revised its full-year growth outlook down to 4.5% to 6.5%, from a previous estimate of 5.5% to 7.5%, citing the impact of the enVista product recall [4] - On the same day, the stock price fell by $2.16 per share, or 15.74%, closing at $11.56 [5] Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Bausch + Lomb's practices, emphasizing its long history of fighting for victims of securities fraud [6]

Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential securities fraud and unlawful business practices following significant financial losses and a product recall [1][3]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a stark contrast to an adjusted net income of $24 million in Q1 2024 [3]. - The company has revised its full-year growth outlook to a range of 4.5% to 6.5% year-over-year, down from a previous guidance of 5.5% to 7.5% [3]. Stock Price Movement - Following the announcement of a voluntary recall of intraocular lenses due to toxic anterior segment syndrome, Bausch + Lomb's stock price dropped by $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [2]. - After the release of Q1 2025 financial results, the stock price fell further by $2.16 per share, or 15.74%, closing at $11.56 on April 30, 2025 [4].